CCL25 Protein (AA 24-150)

Produktnummer ABIN2666903

Dieses Recombinant CCL25-Protein wird in Escherichia coli (E. coli) exprimiert.

Kurzübersicht für CCL25 Protein (AA 24-150) (ABIN2666903)

Target: CCL25 (Chemokine (C-C Motif) Ligand 25 (CCL25))

Protein-Typ: Recombinant

Biologische Aktivität: Active

Spezies: Human

Quelle: Escherichia coli (E. coli)

Applikation: Flow Cytometry (FACS)

Reinheit: > 98 % , as determined by Coomassie stained SDS-PAGE.

Produktdetails

Proteineigenschaft: AA 24-150

Sterilität: 0.22 μm filtered

Endotoxin-Niveau:

Less than 0.01 ng per μg cytokine as determined by the LAL method.

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Kommentare:

Biological activity: Bioactivity was measured by its property to chemoattract BaF3-hCCR9 transfectants in a dose dependent manner.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Rekonstitution: For maximum results, quick spin vial prior to opening. Stock solutions should be prepared at no less than 10 μg/mL in sterile buffer (PBS, HPBS, DPBS, and EBSS) containing carrier protein such as 1 % BSA or HSA. After dilution, the cytokine can be stored between 2 °C and 8 °C for one month or from -20 °C to -70 °C for up to 3 months.

Buffer: 0.22 μm filtered protein solution is in PBS.

Handhabung: Avoid repeated freeze/thaw cycles.

Lagerung: -20 °C

Informationen zur Lagerung: Unopened vial can be stored between 2°C and 8°C for three months, at -20°C for six months, or at -70°C for one year.

Antigendetails

Target: CCL25 (Chemokine (C-C Motif) Ligand 25 (CCL25))

Andere Bezeichnung: CCL25

Hintergrund: CCL25 (TECK) binds to CCR9, the only known receptor for TECK. CCR9 is expressed by a small population of circulating memory CD4+ and CD8+ lymphocytes expressing the intestinal homing receptor α4β7. Therefore, CCL25 is a key regulator for CCR9+CD4+ α4β7 T cell homing to the small intestine. In addition, CCL25 induces adhesion of CD103+ (αEβ7) on CD8 intraepithelial lymphocytes to its epithelial ligand E-cadherin. In inflammatory bowel diseases (IBD), as in celiac and Crohn's diseases, the proportion of CCR9+ cells in the peripheral blood and in the gut seems to be inversed, there is a lower frequency of CCR9+CD4+ T cells in the gut mucosa than in the peripheral blood. Also, a decrease in CCR9+CD4+ T cells occurs in the gut of HIV-infected patients. This decrease correlates with a lower expression of CCL25 by inflamed gut endothelial cells. Unusual expression of CCL25 in the liver occurs in primary sclerosis cholangitis (extra-intestinal complication of IBD). In this way, human T cells activated in the gut can be recruited to liver endothelium. Functional expression of CCR9 has been detected in melanoma derived cells, and it has been associated to small intestine metastatic melanoma processes. In addition, CCR9 is expressed by ovarian, breast, and prostate cancer cells.

Molekulargewicht: The 128 amino acid recombinant protein has a predicted molecular mass of approximately 14.3 kDa. The DTT-reduced and non-reduced protein migrate at approximately 16 and 17 kDa by SDS-PAGE respectively. The N-terminal amino acid is Met.